NovaBridge Biosciences ADR (NBP)
NASDAQ: NBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NBP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $96.28M
- EPS (TTM)
- -$0.69
- Dividend yield
- None
- 52-week range
- 0.751 – 5.19
- Day range
- 0.825 – 0.9803
- Volume / Avg
- 991.51K / 515.66K
- Beta
- —
- Shares outstanding
- 116.00M
52-week range
NBP stock today
NovaBridge Biosciences (NBP) closed at $0.83 on Nov 20, down 5.66% (-$0.0498), versus the S&P 500's 3.70% decline. At this level, NBP sits near the bottom of its 52-week range of $0.751 to $5.19: 84.0% below the high, set on Jan 6, 2026 and 10.5% above the low. NBP is down 79.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.4%.
NovaBridge Biosciences has posted a net loss over the last twelve months (EPS of -$0.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NovaBridge Biosciences
Company profileNovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Srishti Gupta M.D.
- Headquarters
- Rockville, MD
- Employees
- 30
- IPO year
- 2020
- Website
- novabridge.com
Financial highlights
Full financialsNovaBridge Biosciences reported a net loss of $46.3 million, compared with a loss of $22.2 million a year earlier. Diluted earnings per share came in at -$0.21.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $632.00K | $-1.55M | $13.81M |
| Growth | — | — | +140.75% | -111.23% | -94.16% |
| Net income | $-46.27M | $-22.23M | $-207.73M | $-371.05M | $-365.87M |
| EPS (diluted) | $-0.21 | $-0.12 | $-1.09 | $-1.96 | $-2.09 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$8.67+944.58%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
NBP news
All NBP news- Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMDGlobeNewswire
- I-Mab Appoints Charles Silberstein as Chief Financial Officer Effective November 2, 2026Nasdaq
- NovaBridge Names Chuck Silberstein CFO To Succeed Kyler Lei, Shares Jump In Pre-marketNasdaq
- NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial OfficerGlobeNewswire
- I-Mab Reports Mature Phase 1b Data at ESMO 2026Nasdaq
- NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational DevelopmentGlobeNewswire
- Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous NeoplasiaGlobeNewswire
- Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic KeratitisGlobeNewswire
NovaBridge Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PDSBPDS Biotechnology Corporation | 0.7774 | -3.70% | $95.39M | vs NBP |
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs NBP |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs NBP |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs NBP |
| DERMJourney Medical Corporation | 3.30 | -7.04% | $93.16M | vs NBP |
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs NBP |
| CLLSCellectis S.A. ADR | 0.9209 | -7.89% | $92.76M | vs NBP |
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs NBP |
Indexes, lists and sector
NovaBridge Biosciences stock FAQ
What is NovaBridge Biosciences's stock price today?
NBP last traded at $0.83 as of Nov 20, 4:00 PM EST, down 5.66% on the day. Prices are delayed at least 15 minutes.
Who is NovaBridge Biosciences's CEO?
Dr. Srishti Gupta M.D. is the chief executive officer of NovaBridge Biosciences ADR, which has about 30 employees.
What is the NBP 52-week high?
The 52-week high for NBP is $5.19 and the 52-week low is $0.751. The stock is currently 84.0% below its high.